EP1450793A2 - Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale - Google Patents

Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale

Info

Publication number
EP1450793A2
EP1450793A2 EP02799727A EP02799727A EP1450793A2 EP 1450793 A2 EP1450793 A2 EP 1450793A2 EP 02799727 A EP02799727 A EP 02799727A EP 02799727 A EP02799727 A EP 02799727A EP 1450793 A2 EP1450793 A2 EP 1450793A2
Authority
EP
European Patent Office
Prior art keywords
use according
stroke
treatment
blood pressure
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02799727A
Other languages
German (de)
English (en)
Inventor
Joachim Schrader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of EP1450793A2 publication Critical patent/EP1450793A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to the use of antihypertensives - in particular substances for inhibiting the renin-angiotensin system (angiotensin receptor blockers, ACE inhibitors, vasopeptidase inhibitors) and combinations with these and other antihypertensive agents in the treatment of acute stroke for the reduction the risk of cerebro resp. cardiovascular events and improvement of the patient's neurological survival.
  • substances for inhibiting the renin-angiotensin system angiotensin receptor blockers, ACE inhibitors, vasopeptidase inhibitors
  • Stroke is the 3rd leading cause of death in Germany. Many patients retain severe neurological deficits, only a few become fully able to work again. More than 1 million patients in Germany currently have to live with permanent disabilities as a result of the stroke, which often leads to professional decline and social isolation. The numbers underline the importance of dealing with the basics, with therapy, with the prevention and aftercare of the stroke. The most common causes of stroke are ischemic haemorrhages with 80-90%. The recurrence rate is 5% per year after a transient ischemic attack, 10% after an overt stroke, and 15% after a severe stroke. 50-75% of the affected patients become somewhat independent again, 25% remain in need of care.
  • preferred substances for inhibiting the renin-angiotensin system are:
  • Angiotensin receptor blockers ACE inhibitors and vasopeptidase inhibitors.
  • candesartan irbesartan, valsartan, losartan
  • Fosinopril and omapatrilat and their pharmacologically acceptable salts and esters.
  • the substance for inhibiting the renin-angiotensin system should still be present during the acute phase of the stroke, preferably 0 to 72 hours, particularly preferably 0 to 36, and 0 to 24 hours after the stroke has occurred until at least 7 days after the stroke be administered.
  • acute stroke means in particular cerebral ischemia and particularly preferably acute cerebral ischemia.
  • the treatment of patients with elevated blood pressure is particularly preferred, in particular of patients with a systolic blood pressure of over 180 mmHg and / or a diastolic blood pressure of over 105 mmHg.
  • the dose can be increased to 1 tablet or 2 tablets once a day if blood pressure values (> 160 mmHg systolic and / or> 100 mmHg diastolic) are not sufficiently lowered (corresponds to 8 mg or 16 mg candesartan cilexetil or Placebo).
  • a combination therapy can be started from the 7th day of therapy for blood pressure values of> 160 mmHg systolic and / or> 100 mmHg diastolic.
  • the basis for changes in therapy is the average of at least 3 blood pressure measurements per day.
  • Exemplary combination partners are listed below:
  • Salureticum Hydrochlorothiazide: (e.g. Esidrix) 12.5 - 25 mg,
  • Felodipine (e.g. Modip) 2.5 - 5 mg
  • Beta blocker Metoprolol: (e.g. Beloc) 50 - 100 mg.
  • the desired reduction in blood pressure is 10-15% within 24 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'une substance d'inhibition du système rénine-angiotensine, lors du traitement de l'apoplexie cérébrale.
EP02799727A 2001-11-23 2002-11-25 Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale Withdrawn EP1450793A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10157474 2001-11-23
DE10157474 2001-11-23
DE10158030 2001-11-27
DE10158030 2001-11-27
PCT/EP2002/013238 WO2003043615A2 (fr) 2001-11-23 2002-11-25 Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale

Publications (1)

Publication Number Publication Date
EP1450793A2 true EP1450793A2 (fr) 2004-09-01

Family

ID=26010631

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02799727A Withdrawn EP1450793A2 (fr) 2001-11-23 2002-11-25 Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale

Country Status (9)

Country Link
US (1) US20050009893A1 (fr)
EP (1) EP1450793A2 (fr)
JP (1) JP2005511631A (fr)
AU (1) AU2002364381A1 (fr)
BR (1) BR0214383A (fr)
CA (1) CA2467095A1 (fr)
MX (1) MXPA04004844A (fr)
PL (1) PL370270A1 (fr)
WO (1) WO2003043615A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001015674A2 (fr) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Utilisation d'inhibiteurs du systeme renine-angiotensine dans la prevention de manifestations cardio-vasculaires
US8763642B2 (en) 2010-08-20 2014-07-01 Integenx Inc. Microfluidic devices with mechanically-sealed diaphragm valves
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) * 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
CA2048699A1 (fr) * 1990-09-04 1992-03-05 Abraham Sudilovsky Methode de prevention ou de traitement des maladies cerebro-vasculaires faisant appel au ceronapril
US20010018448A1 (en) * 1990-12-14 2001-08-30 Smithkline Beecham P.L.C. Medicament
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
ES2198564T3 (es) * 1996-03-29 2004-02-01 Smithkline Beecham Corporation Dihidrato de eprosartan y un procedimiento para su produccion y formulacion.
DE69830069T3 (de) * 1997-10-17 2012-02-09 Ark Therapeutics Ltd. Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
JP4588877B2 (ja) * 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Ａｄｐ−受容体抗血小板物質と抗高血圧薬の組合せ投与による脳梗塞の予防
FR2783422A1 (fr) * 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
WO2001005428A1 (fr) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
WO2001015674A2 (fr) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Utilisation d'inhibiteurs du systeme renine-angiotensine dans la prevention de manifestations cardio-vasculaires
WO2001072335A2 (fr) * 2000-03-28 2001-10-04 Queen's University At Kingston Procedes de mise en oeuvre de neuroprotection
EP1326604A2 (fr) * 2000-04-12 2003-07-16 Novartis AG Combinaison d'au moins 2 composes selectionnes d'un antagoniste de recepteurs at1 ou d'un inhibiteur de ace ou d'un hmg-co reductase
BR0017386A (pt) * 2000-12-18 2004-01-13 Novartis Ag Combinação terapêutica de amlodipina e benazepril
DE10115668A1 (de) * 2001-03-29 2002-10-10 Max Delbrueck Centrum Mittel zur Behandlung des Schlaganfalls

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO03043615A3 *

Also Published As

Publication number Publication date
JP2005511631A (ja) 2005-04-28
CA2467095A1 (fr) 2003-05-30
WO2003043615A2 (fr) 2003-05-30
US20050009893A1 (en) 2005-01-13
PL370270A1 (en) 2005-05-16
AU2002364381A1 (en) 2003-06-10
WO2003043615A3 (fr) 2004-02-19
BR0214383A (pt) 2004-11-03
MXPA04004844A (es) 2004-07-30

Similar Documents

Publication Publication Date Title
EP1940398A1 (fr) Utilisation de pramipexol pour traiter le syndrome des jambes sans repos (rls) modere a severe
WO2000002542A2 (fr) Agent a effet antidepressif
DE10108215A1 (de) Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym
EP1450793A2 (fr) Traitement de l'hypertonie durant la phase aigue d'apoplexie cerebrale
DE10018401A1 (de) Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
DE69624253T2 (de) Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
DE60028928T2 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
EP1014989B1 (fr) Antagoniste d'endotheline et systeme renine-angiotensine inhibiteur presentes sous forme de preparation pharmaceutique
DE69522764T2 (de) Verwendung vom einem Bicycloheptan-Derivat
DE69620186T2 (de) Neue medizinische verwendung
KR20070053239A (ko) 사구체 질환 치료제
DE60117541T2 (de) Candesartan zur Behandlung von Migräne
DE69725613T2 (de) Neue therapeutische verwendung eines thienylcyclohexylaminderivates
DE60122252T2 (de) Verfahren zur behandlung von neurodegeneration
WO2002007713A2 (fr) Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre
Elsafa et al. Protective effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) on microalbuminuria in diabetic patients
EP0508511B1 (fr) Compositions contenant du verapamil et du trandolapril
DE69923982T2 (de) Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
DE60203192T2 (de) Zubereitungen mit lisinopril und ungemahlenem dcpd
DE60012183T2 (de) Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen
Rahn Recent intervention studies with antihypertensive drugs and their influence on guidelines
DE4339848C2 (de) Arzneimittel zur optimierten Behandlung eines erhöhten Blutdrucks und zur Verhütung von Folgeerkrankungen
JPWO2008016171A1 (ja) 腎機能障害予防・治療剤
EP1531809A1 (fr) Antagonistes de recepteur at1 permettant de prevenir des accidents vasculaires cerebraux secondaires
Baer Arterielle Hypertonie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040609

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20061027

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070307